Vera Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Atacicept is on track for FDA approval in July, with no major review or supply issues anticipated. The commercial strategy targets a broad U.S. market, leveraging a patient-friendly auto-injector and robust payer engagement. Pipeline efforts include expanded indications and longer-acting formulations.
-
Atacicept is on track for a July 2026 commercial launch in IgAN, supported by strong phase III efficacy and safety data, robust financials, and a dedicated commercial team. Ongoing trials and new formulations aim to expand its reach, with updated guidelines and additional data expected this year.
Fiscal Year 2025
-
Atakicept's positive Phase III results in IgAN nephropathy support a BLA filing, with a potential July PDUFA date. The drug offers a novel, safe, and effective B cell-targeted therapy, with an autoinjector launch planned and expansion into other autoimmune kidney diseases underway.
-
Phase 3 data for atacicept in IgA nephropathy showed strong efficacy and safety, supporting a planned U.S. launch in 2026. The pipeline is expanding into broader kidney and autoimmune indications, with monthly and long-interval dosing in development.
-
Recent clinical data show atacicept achieved significant reductions in proteinuria and hematuria, with GFR stability over two years and a favorable safety profile. Regulatory filings are underway, and broader studies in autoimmune kidney diseases are ongoing, with more data expected into 2026.
-
Atacicept's Phase III interim results show strong efficacy and safety in IgA nephropathy, with significant reductions in proteinuria and favorable biomarker outcomes across all patient subgroups. The product is highly anticipated by nephrologists, and the company is financially prepared for a 2026 launch and further pipeline expansion.
-
Atacicept has demonstrated robust, consistent efficacy in IgA nephropathy, with a BLA filing planned for Q4 and anticipated market entry by mid-next year. Commercial preparations are advanced, the auto-injector is well received, and the pipeline is expanding into broader kidney and autoimmune indications.
-
Atacicept showed strong phase III efficacy and safety in IgAN, with at-home dosing and robust GFR data supporting its use as a foundational therapy. Regulatory filing is planned for Q4, with commercial launch targeted for mid-2026 and significant market opportunity anticipated.
-
The ORIGIN phase III trial of atacicept in IgA nephropathy showed a 46% reduction in proteinuria at week 36, with a favorable safety profile and no increase in serious infections. These results support a planned BLA submission and position atacicept as a potential new standard for high-risk IgAN patients.
-
Phase III data for atacicept in IgA nephropathy is expected in Q2, supporting a BLA filing in the second half of the year. Commercial and regulatory strategies are well advanced, with pipeline expansion targeting broader renal and autoimmune indications.
-
Atacicept, a dual BAFF/APRIL modulator, is advancing in phase III for IgAN with strong two-year efficacy and safety data, aiming for a 2026 launch. Pipeline expansion includes new indications, monthly dosing, and a next-gen molecule, VT109, supported by robust financials.
Fiscal Year 2024
-
Atacicept has shown two-year kidney function stabilization in IgA nephropathy, with phase 3 data expected in Q2 2025 to support a BLA filing. The company is preparing for commercialization in 2026, targeting a $6–$10 billion market and exploring expanded indications.
-
Atacicept has set a new standard in IgA nephropathy by demonstrating stable GFR over two years and high safety, with phase III data expected in Q2 next year. Expansion into broader and adjacent autoimmune kidney diseases could increase the addressable U.S. population to nearly 250,000 patients.
-
The ORIGIN Phase IIb study of atacicept in IgA nephropathy showed sustained reductions in pathogenic IgA, proteinuria, and hematuria, with near-normal stabilization of kidney function over 96 weeks and a strong safety profile. At-home, weekly administration was highly acceptable, and phase III results are expected in 2025.
-
Atacicept is advancing as a potential best-in-class therapy for IgAN and other autoimmune kidney diseases, with phase 3 data expected in 2025 and a commercial launch targeted for 2026. Expansion includes new trials in broader patient populations and additional indications, supported by strong financials and regulatory momentum.
-
Atacicept, a dual BAFF/APRIL inhibitor, demonstrated strong efficacy in IgA nephropathy, with significant reductions in immune complexes, proteinuria, and hematuria, and stable GFR over 72 weeks. Two-year data and a commercial launch are anticipated in 2026.